A Phase 1/2 Study of ARQ 092 in Patients With Overgrowth Diseases and Vascular Anomalies With Genetic Alterations of the PI3K/AKT Pathway
Phase of Trial: Phase I/II
Latest Information Update: 12 Jun 2017
At a glance
- Drugs ARQ 092 (Primary)
- Indications Growth disorders; Proteus syndrome
- Focus Adverse reactions
- Sponsors ArQule
- 07 Jun 2017 According to an ArQule Inc, media release, the first patient has been dosed in this trial.
- 03 May 2017 According to an ArQule Inc, media release, the first patient has been identified in this trial.
- 01 May 2017 Status changed from not yet recruiting to recruiting.